During the last few weeks, most of the multi-national pharmaceutical companies have reported results for 2017, which has provided us with the opportunity to update our industry statistics and drug database. This report provides the first publication of global and US rankings of the top 15 drug companies for 2017. Comparisons are made with historic data to show how different company strategies have evolved. In addition, analysis has been provided for the evolution of therapeutic biopharmaceutical drugs, which saw sales rise 7% to $197bn, representing 24% of the market, and driven by growth in antibody-derived drugs.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
2017 industry statistics
- Published:
11 Apr 2018 -
Author:
Martin Hall -
Pages:
16
During the last few weeks, most of the multi-national pharmaceutical companies have reported results for 2017, which has provided us with the opportunity to update our industry statistics and drug database. This report provides the first publication of global and US rankings of the top 15 drug companies for 2017. Comparisons are made with historic data to show how different company strategies have evolved. In addition, analysis has been provided for the evolution of therapeutic biopharmaceutical drugs, which saw sales rise 7% to $197bn, representing 24% of the market, and driven by growth in antibody-derived drugs.